Skip to main content

Table 2 Overall survival estimates in de novo stage IV patients on univariate and multivariate models

From: Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer

 

Univariate

Multivariate

Variable

HR

95%CI

P

HR

95% CI

P

Luminal-like

1

  

1

  

HER2–enriched

2.0

1.4-2.8

< 0.0001

2.2

1.5-3.1

< 0.0001

Triple negative

4.2

2.8-6.2

< 0.0001

4.3

2.9-6.5

< 0.0001

cT1-3 vs. cT4

0.7

0.5-0.9

0.011

   

NG 1–2 vs. NG 3

0.9

0.5-1.4

0.5386

   

LVI

  focal vs. no

0.6

0.3-1.4

0.2649

   

  Prominent vs. no

0.5

0.3-1.0

0.0616

   

Lymph node involvement

1.1

0.8-1.5

0.6471

   

CEA elevated vs. normal

1.1

0.8-1.5

0.3969

   

CA 153 elevated vs. normal

1.1

0.8-1.4

0.6379

   

Metastasis

  Liver, yes vs. no

2.3

1.7-3.2

< 0.0001

1.9

1.4-2.5

0.0001

  Lung, yes vs. no

1.7

1.3-2.2

0.0004

1.4

1.1-1.9

0.0153

  Brain, yes vs. no

1.5

1.1-2.3

0.0256

1.3

0.9-1.9

0.1728

  Bone, yes vs. no

1.3

0.9-1.8

0.1016

1.8

1.3-2.5

0.0007

*Local treatment, yes vs. no

0.5

0.4-0.6

< 0.0001

0.6

0.4-0.8

0.0008

  1. Note: *Local treatment: surgery, radiotherapy, or both.